Zenidolol

Zenidolol

SCHEMBL29558331

Cc1ccc(OCC(O)C(C)NC(C)C)c2c1CCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 7/20 1.00
ADRB1 P08588 5/20 1.00
ADRB3 P13945 3/20 1.00
CYP2D6 P10635 2/20 1.00
TSHR P16473 2/20 1.00
KDM4E B2RXH2 2/20 1.00
ADRA2A P08913 1/20 1.00
TP53 P04637 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
NFKB1 P19838 1/20 1.00
HIF1A Q16665 1/20 1.00
NPSR1 Q6W5P4 2/20 0.97
MEN1 O00255 1/20 0.97
LMNA P02545 1/20 0.97
PMP22 Q01453 1/20 0.97
KMT2A Q03164 1/20 0.97
RXRG P48443 7/20 0.44
RXRA P19793 6/20 0.44
RXRB P28702 6/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Zenidolol SCHEMBL146178 1.00 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP2D6TSHR
Zenidolol SCHEMBL8027938 1.00 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP2D6TSHR
Zenidolol SCHEMBL14941581 1.00 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP2D6TSHR
Zenidolol SCHEMBL15058356 1.00 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP2D6TSHR
Zenidolol SCHEMBL29387637 1.00 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP2D6TSHR
Zenidolol SCHEMBL5485188 0.99 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP2D6TSHR
Zenidolol SCHEMBL29686378 0.99 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP2D6TSHR
Zenidolol SCHEMBL31074300 0.99 ADRB2 (1.00) ADRB2ADRB1ADRB3CYP2D6TSHR
SCHEMBL15549338 0.85 ADRB2 (0.74) ADRB2ADRB1ADRB3CYP2D6TSHR
SCHEMBL11266032 0.85 ADRB2 (0.74) ADRB2ADRB1ADRB3CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4509118-A2 HIGH-PURITY PEG LIPIDS AND USES THEREOF ModernaTX, Inc. (US) 2025-02-19 EP disclosed
WO-2024189434-A1 USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2024-09-19 WO disclosed
WO-2024102883-A1 METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING STRESS-RELATED DISORDER YALE UNIVERSITY (US) 2024-05-16 WO disclosed
CN-117999073-A Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway 慢性呼吸道治疗有限公司 2024-05-07 CN disclosed
CN-111712241-B Sigma-1 receptor agonist systolic blood pressure therapy 阿纳韦克斯生命科学公司 2024-02-13 CN disclosed
CN-115337267-A Preparation method and application of acid-responsive drug delivery platform based on liposome nano-vesicles 中国科学技术大学 2022-11-15 CN disclosed
CN-110003172-B Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators 同步制药公司 2022-04-01 CN disclosed